Cell Death Dis: Anti-cancer effect of statins in p53 mutant T-type lymphoma

Long-standing research has found that statins may have anti-tumor activityThere is currently some epidemiological evidence that statin use is associated with reduced mortality rates for many distributive cancers, including colorectal, breast, lung, prostate and kidney cancersclinical studies based on cell and animal models have found that statins directly inhibit the development of prostate and pancreatic cancersTP53 is the most common mutant gene in human cancerMost p53 mutations are false mutations (mutp53), which not only lose the anti-cancer function of p53, but also often have cancer-promoting acquiring function (GOF), which promotes the development of cancer, EMT, invasion, metabolism, metastasis, metastasis, and chemical resistanceThe stabilization of the Mutp53 protein is a prerequisite for GOFThe GOF effect of mutp53 is mainly manifested in the stable mutp53 protein can enhance the path of methicillin, and this mechanism also provides a theoretical basis for exploring HMGCoA reductase inhibitors in statins as an anti-cancer drug for mutp53 tumorsin the study, researchers revealed the therapeutic effects of statins in mouse models of advanced clinical T-cell lymphoma that expressed two different GOFmutp53 allelesT lymphoma sympathising expression p53 R248Q mutant treated with reschvasttin alone was able to obtain a certain degree of p53 allele selectivity and short-term anti-tumor effect, which was not found in tumors that expressed p53 R172H mutant; In vitro sensitivity of statins is not a predictor of sensitivity in the body, and the results of subcutaneous transplant tumors can be used as predictive indicatorsthis study suggests that adding statins to combination therapy may improve anti-tumor effects, while identifying alleles and tumor types that are most sensitive to statins in stable p53 mutants